TrialNarra J2025

Role of phosphodiesterase-3 inhibitor in cardiorespiratory fitness and functional class of patients with pulmonary hypertension: A randomized, double-blind, placebo-controlled trial.

Sefri N Sofia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.